Pederson Christopher
Known title: SVP, President SEMCIK: 0001756776
Associated companies
Transaction History
| AVNT | ▼ Sell | Other | 455 | $15K | 6/27/2025 | View on chart |
| AVNT | ▼ Sell | Other | 827 | $31K | 3/28/2025 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 4,450 | — | 2/14/2025 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,410 | $61K | 2/14/2025 | View on chart |
| AVNT | ▼ Sell | Other | 325 | $13K | 12/30/2024 | View on chart |
| AVNT | ▼ Sell | Other | 105 | $5K | 9/27/2024 | View on chart |
| AVNT | ▼ Sell | Other | 22 | $948 | 6/27/2024 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 4,800 | — | 2/8/2024 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,668 | $62K | 2/8/2024 | View on chart |
| AVNT | ▼ Sell | Other | 318 | $13K | 12/28/2023 | View on chart |
| AVNT | ▼ Sell | Other | 171 | $6K | 9/28/2023 | View on chart |
| AVNT | ▼ Sell | Other | 104 | $4K | 6/29/2023 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 5,950 | — | 2/10/2023 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 2,014 | $76K | 2/10/2023 | View on chart |
| AVNT | ▼ Sell | Other | 338 | $12K | 12/29/2022 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 5,350 | — | 2/11/2022 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,774 | $93K | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.